

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/026415 A1

(51) International Patent Classification:

A61K 31/702 (2006.01) *A61P 3/06* (2006.01)
A61L 33/12 (2006.01) *A61P 3/10* (2006.01)
A61K 45/06 (2006.01) *A61P 5/14* (2006.01)
A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2021/043228

(22) International Filing Date:

26 July 2021 (26.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/059,264 31 July 2020 (31.07.2020) US

(71) Applicant: **ABBOTT LABORATORIES** [US/US]; 100
Abbott Park Road, Abbott Park, Illinois 60064-3500 (US).

(72) Inventors: **MANZANO, Manuel**; Calle Cartujo nº 48
CD-163, 18151 Dilar Granada (ES). **HERNANDEZ, En-
rique**; Camino de Purchil 42, Urbanización Nenufares at-
ico 52, 18151 Granada Granada (ES). **LÓPEZ PEDROSA,
José María**; C/ Luciano nº 14, 18190 Cenés de la Vega
Granada (ES). **RUEDA CABRERA, Ricardo**; C/Brazal, 2,
18008 Granada Granada (ES). **BUCK, Rachael**; 3710 Peak
Ridge Drive, Gahanna, Ohio 43230 (US).

(74) Agent: **KOZLOWSKI, Holly**; 41 South High Street,
Porter Wright Morris & Arthur LLP, Columbus, Ohio
43215 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE




FIG. 8

(57) Abstract: A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the at least one HMO is administered in an amount effective to reduce de novo lipogenesis in the subject. The at least one HMO can be administered to the subject directly or in a nutritional composition.



WO 2022/026415 A1